Trials / Unknown
UnknownNCT03932071
Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
The Efficacy of New Adjuvant Chemotherapy of Osteosarcoma Combined With Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been widely used in the treatment of metastatic bone tumors. In addition to its inhibition of tumor osteoclasis, it also produces certain killing of tumor cells. effect. Foreign studies have shown that zoledronic acid also has a killing effect on osteosarcoma and has a certain inhibitory effect on distant metastasis. We hope that it can reduce tumor recurrence and lung metastasis through this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoledronic Acid |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2020-01-01
- Completion
- 2023-01-01
- First posted
- 2019-04-30
- Last updated
- 2019-05-06
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03932071. Inclusion in this directory is not an endorsement.